Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies

Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies

Background: There is considerable interest in the molecular evaluation of solid tumors in pediatric cases. Although clinical trials are in progress for targeted therapies against neuroblastoma (NB), novel therapeutic strategies are needed for high-risk cases that are resistant to therapy. The aim of...

Full description

Bibliographic Details
Main Authors:	Tekincan Aktas, Deniz Kızmazoglu, Safiye Aktas, Aylin Erol, Efe Serinan, Ozde Gokbayrak, Sefayi Merve Ozdemir, Zekiye Altun, Erdener Ozer, Emre Cecen, Dilek Ince, Nur Olgun
Format:	Article
Language:	English
Published:	IMR Press 2023-08-01
Series:	Frontiers in Bioscience-Landmark
Subjects:	neuroblastoma mutation high-throughput nucleotide sequencing therapy anaplastic lymphoma kinase erbb-2 braf-kiaa1549 fusion protein dna mutational analysis
Online Access:	https://www.imrpress.com/journal/FBL/28/8/10.31083/j.fbl2808171

Similar Items

Incidence of kiaa1549‐braf fusion gene in Egyptian pediatric low grade glioma
by: Hala Taha, et al.
Published: (2015-12-01)

Molecular Heterogeneity in Neuroblastoma and Its Clinical Significance
by: Tekincan Çağrı Aktaş, et al.
Published: (2023-08-01)

A molecular study of pediatric pilomyxoid and pilocytic astrocytomas: Genome-wide copy number screening, retrospective analysis of clinicopathological features and long-term clinical outcome
by: Essam AlShail, et al.
Published: (2023-02-01)

Integrated genomic analysis reveals actionable targets in pediatric spinal cord low-grade gliomas
by: Misove Adela, et al.
Published: (2022-09-01)

Promises of targeted therapy for low grade gliomas in children
by: E. F. Valiakhmetova, et al.
Published: (2019-07-01)

Anaplastic thyroid cancer. Is there a light at the end of the tunnel?
by: A. L. Pylev, et al.
Published: (2020-04-01)

Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report
by: Daniele Barbaro, et al.
Published: (2024-07-01)

Whole Exome Sequencing Analysis of Good and Bad Prognostic Neuroblastoma Patients (on the Behalf of Turkish Pediatric Oncology Group)
by: Zekiye Altun, et al.
Published: (2018-12-01)

V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia
by: Neeraj Arora, et al.
Published: (2015-01-01)

Neuroblastoma-targeted Anticancer Drug Delivery
by: Safiye Aktaş, et al.
Published: (2021-12-01)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
by: Matthias Lang, et al.
Published: (2023-03-01)

The Effects of Oleuropein on Different Clinically Types of Human Neuroblastoma Cells
by: Zekiye Altun, et al.
Published: (2018-12-01)

Comparison of Cytotoxic and Ototoxic Effects of Lipoplatin and Cisplatin in Neuroblastoma In Vivo Tumor Model
by: Hande Evin Eskicioğlu, et al.
Published: (2022-09-01)

Braf protein mutation and its significancy within patients with melanoma
by: Julia Kuchnicka, et al.
Published: (2022-08-01)

Investigation of the effectiveness of hyperthermic intraperitoneal chemotherapy in experimental colorectal peritoneal metastasis model
by: Manoğlu Berke, et al.
Published: (2023-05-01)

Identification of Mutation in Neuroblastoma on the Point of Molecular Heterogeneity
by: Tekincan Çağrı Aktaş MD, PhD, et al.
Published: (2023-11-01)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
by: Omer Bayrak, et al.
Published: (2014-08-01)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
by: Daeyoun David Won, et al.
Published: (2017-06-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
by: O. I. Kit, et al.
Published: (2016-06-01)

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
by: Takayo Ota, et al.
Published: (2021-10-01)

BRAF mutation and its inhibitors in sarcoma treatment
by: Haotian Liu, et al.
Published: (2020-07-01)

“Don’t Eat Me” Signals of Neuroblastoma by CD47 for Immune Escape: A Novel Prognostic Biomarker
by: Safiye Aktas, et al.
Published: (2018-12-01)

Oncogenic mutations within the β3‐αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies
by: Biao Zhang, et al.
Published: (2020-10-01)

Editorial: Molecular Genetics of Cutaneous Melanoma: Current Status and Future Direction
by: Cristina Pellegrini, et al.
Published: (2021-12-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
by: Hana Garaj, et al.
Published: (2024-01-01)

Analysis of survival at metastatic melanoma patients treated with vemurafenib: A three year single institution study
by: Gojković Zdenka, et al.
Published: (2018-01-01)

BRAF‐mutated malignant melanoma with chondrosarcomatous differentiation in inguinal nodal metastasis
by: Francesca Abbati, et al.
Published: (2021-04-01)

Evaluation of mutations in KRAS and BRAF genes in Iranian population with diffuse gastric cancer
by: M. Saneipour, et al.
Published: (2019-07-01)

Melanoma: clinical-pathological and molecular analysis in patients of Ibague city, Colombia
by: Carlos Puentes, et al.
Published: (2020-01-01)

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
by: Megha Puri, et al.
Published: (2023-08-01)

Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: Using immunohistochemistry as the diagnostic modality in a significant subset
by: Koushik Chatterjee, et al.
Published: (2017-01-01)

Adequacy of biopsy samples for epidermal growth factor receptor (EGFR) molecular testing in lung adenocarcinoma
by: Tegeltija Dragana, et al.
Published: (2021-01-01)

Targeting ERBB2 mutations in solid tumors: biological and clinical implications
by: Sophie Cousin, et al.
Published: (2018-06-01)

Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements
by: Daisuke Uno, et al.
Published: (2024-09-01)

Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment
by: Fréderic Franconieri, et al.
Published: (2018-08-01)

Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with TwoState-of-the-Art Techniques
by: Nicola L. Schoenewolf, et al.
Published: (2012-06-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
by: Clare Judith Stones, et al.
Published: (2013-05-01)

Activating Mutations and/or Expression Levels of Tyrosine Kinase Receptors GRB7, RAS, and BRAF in Testicular Germ Cell Tumors
by: Alan McIntyre, et al.
Published: (2005-12-01)

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review
by: Nina Yu, et al.
Published: (2024-12-01)